Insider transactions

Michael Jay Ross

CIK 1254452 · last filed 2026-10-08

Michael Jay Ross is a corporate insider who has filed 20 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing, for TRXB, was dated Oct 8, 2026. Across all open-market trades the lifetime net is +$5.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.76M
Companies
7
Total Filings
20
Lifetime Open-Market Net
$5.00M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

ASNS price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O SV HEALTH INVESTORS, LLC
ONE BOSTON PLC, 201 WASHINGTON ST. #3900
BOSTON, MA 02108
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TRXB Director — — — $0 1 2026-10-08
XLO Director — $8.07 — $0 2 2022-06-17
Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Director — $25.59 — $0 2 2019-06-13
STRO Director 180,115 $9.76 $1.76M $0 2 2018-10-01
IVERIC bio, Inc. (OPHT) Delisted Director 3,500 — — $0 5 2018-07-11
Astria Therapeutics, Inc. (CATB) Delisted Director — $8.54 — $0 4 2018-06-07
X4 Pharmaceuticals, Inc (ASNS) Delisted Director 32 $0.08 $2 $5.00M 4 2018-06-07

Holdings By Holder

Who holds the shares on record: the insider directly, and each trust, LLC, partnership or family member reported as an indirect holder on the latest Form 4 that lists them. Holder names come from the filing's footnotes. Rows under No longer reported appeared on earlier filings but not the latest one, usually because the holder was emptied or folded into another; they are not counted in the total.
Symbol Holder Shares Share of Total Reported
STRO By International Life Sciences Fund III (LP1), L.P. 92,302 51.2% 2018-10-01
By SV Life Sciences Fund V, L.P. 86,350 47.9% 2018-10-01
By SV Life Sciences Fund V Strategic Partners, L.P. 1,293 0.7% 2018-10-01
By International Life Sciences Fund III Co-Investment, L.P. 94 0.1% 2018-10-01
By International Life Sciences Fund III Strategic Partners, L.P. 76 0.0% 2018-10-01
Total 180,115
ASNS SV Life Sciences Fund V
See Footnote
 32 100.0% 2017-11-20
Total 32

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2026-10-08 TRXB Grant (A) — $0 EDGAR
2022-06-17 XLO Grant (A) — $0 EDGAR
2021-10-25 XLO Grant (A) — $0 EDGAR
2019-06-13 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Grant (A) — $0 EDGAR
2018-10-01 STRO Mixed +1,824,542 $0 EDGAR
2018-09-27 STRO Grant (A) — $0 EDGAR
2018-07-11 IVERIC bio, Inc. (OPHT) Delisted Grant (A) — $0 EDGAR
2018-06-07 Astria Therapeutics, Inc. (CATB) Delisted Grant (A) — $0 EDGAR
2018-06-07 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
2018-05-21 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).